SCM
GSK icon

Soleus Capital Management’s GSK GSK Stock Holding History

Soleus Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-639,000
Closed -$31.3M – 104
2025
Q4 		$31.3M Buy
639,000
+419,000
+190% +$19.5M 1.16% 22
2025
Q3 		$9.5M Buy
+220,000
New +$8.59M 0.48% 47
2025
Q1 		– Sell
-10,110
Closed -$342K – 84
2024
Q4 		$342K Sell
10,110
-27,390
-73% -$986K 0.02% 76
2024
Q3 		$1.53M Sell
37,500
-377,500
-91% -$15.4M 0.12% 82
2024
Q2 		$16M Buy
415,000
+95,783
+30% +$4.03M 1.41% 28
2024
Q1 		$13.7M Sell
319,217
-959,323
-75% -$39.6M 1.02% 31
2023
Q4 		$47.4M Buy
1,278,540
+335,540
+36% +$12M 5.26% 3
2023
Q3 		$34.2M Buy
+943,000
New +$33.5M 3.15% 7

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Soleus Capital Management's GSK Position: Q1 2026 in Review

Soleus Capital Management sold out of GSK (GSK) in Q1 2026, closing a stake of 639,000 shares — an estimated $31.3M sold.

Soleus Capital Management first reported a position in GSK in Q3 2023 and held it in 8 quarters. The position peaked at $47.4M in Q4 2023. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Soleus Capital Management reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
  • Soleus Capital Management sold 639,000 GSK shares in Q1 2026, an estimated $31.3M.
  • Soleus Capital Management first reported a position in GSK in Q3 2023 and held it in 8 quarters.
  • Soleus Capital Management's GSK position peaked at $47.4M in Q4 2023.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.